<SEC-DOCUMENT>0001193125-20-209792.txt : 20200805
<SEC-HEADER>0001193125-20-209792.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805060729
ACCESSION NUMBER:		0001193125-20-209792
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200805
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			I-Mab
		CENTRAL INDEX KEY:			0001778016
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39173
		FILM NUMBER:		201075490

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
		BUSINESS PHONE:		862160578000

	MAIL ADDRESS:	
		STREET 1:		SUITE 802, WEST TOWER, OMNLVISION
		STREET 2:		88 SHANGKE ROAD, PUDONG DISTRICT
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201210
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d91622d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of August 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission
File Number: <FONT STYLE="white-space:nowrap">001-39173</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">I-MAB</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 802,
West Tower, OmniVision, 88 Shangke Road, Pudong District </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Shanghai, 201210 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>People&#146;s Republic of China </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT> <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">I-MAB</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jielun Zhu</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jielun Zhu</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director and Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: August&nbsp;5, 2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit Index </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibit 99.1&#151;Press Release </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d91622dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g91622g0804183017047.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth
Hormone Deficiency </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SHANGHAI and GAITHERSBERG, MD. &#151; August&nbsp;4, 2020 &#151; <FONT STYLE="white-space:nowrap">I-Mab</FONT> (the
&#147;Company&#148;) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration (NMPA) has
accepted its pivotal trial application for eftansomatropin (also known as TJ101) as a weekly treatment for growth hormone deficiency in pediatric patients (PGHD). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eftansomatropin is an innovative long-acting recombinant human growth hormone (rhGH) with a novel molecular format utilizing Genexine&#146;s patented
half-life extension hyFc<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> fusion technology, which stimulates the production of insulin-like growth factor 1 <FONT STYLE="white-space:nowrap">(IGF-1)</FONT> in the liver, alongside
growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte activities that stimulate bone growth. Additionally, preliminary research and trials have proved that as a natural protein based rhGH, eftansomatropin has not
shown safety concerns typically associated withconventional pegylated rhGH drugs on the market, while maintaining comparable efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 3 trial
is a multi-center, randomized, open-label, active-controlled clinical study designed to assess the safety, efficacy and pharmacokinetics of eftansomatropin in PGHD. The primary objective is to demonstrate
<FONT STYLE="white-space:nowrap">non-inferiority</FONT> of eftansomatropin administered in subcutaneous injection, compared to the active control Norditropin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (somatropin), a daily rhGH
marketed in China. About 165 subjects will be enrolled and treated in the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The China NMPA&#146;s acceptance of this pivotal IND for
eftansomatropin represents an important step towards bringing this innovative product to the Chinese market as planned,&#148; said Dr.&nbsp;Joan Shen, CEO of <FONT STYLE="white-space:nowrap">I-Mab.</FONT> &#147;With eftansomatropin, we will be able
to potentially address a substantial unmet medical need with a safer, highly differentiated, and convenient therapy for pediatric patients suffering from the growth hormone deficiency&#148;, Shen added. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company owns the rights of eftansomatropin from Genexine Inc. (KOSDAQ: 095700) for development, manufacturing and commercialization in China. Genexine has
previously completed three clinical trials with eftansomatropin in Europe and Asia, including one Phase 1 trial in healthy adult volunteers, one Phase 1b/2 multi-regional trial in adults with growth hormone deficiency (NCT02946606), and one Phase 2
multi-regional trial in PGHD (NCT03309891). Overall, eftansomatropin was shown to be well-tolerated, and has met clinical efficacy endpoints by weekly or twice-monthly administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to Frost&nbsp;&amp; Sullivan, PGHD affected approximately 3.4&nbsp;million patients in Greater China, but only 3.7% of all PGHD patients were
receiving growth hormone replacement therapy, which primarily consists of daily injections of rhGH. Recombinant human growth hormone therapy has been included in the National Reimbursement Drug List in China. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About eftansomatropin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Eftansomatropin is a potential highly differentiated long-acting recombinant human growth hormone being developed as a more convenient and effective therapy
for growth hormone deficiency. Like endogenous growth hormone, eftansomatropin stimulates the production of insulin-like growth factor 1 in the liver, which has growth-stimulating effects on a variety of tissues, including osteoblast and chondrocyte
activities that stimulate bone growth. <FONT STYLE="white-space:nowrap">IGF-1</FONT> is a reliable pharmacodynamic marker and the key mediator of growth-promoting activity of eftansomatropin. Eftansomatropin is based on Genexine&#146;s patented hyFc<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology. The hyFc part consists of a portion of human immunoglobulin D (&#147;IgD&#148;) and G4 (&#147;IgG4&#148;). The former contains a flexible hinge, and the latter is responsible for
half-life extension through neonatal Fc receptor (&#147;FcRn&#148;)-mediated recycling. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">I-Mab</FONT> (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on developing biologics of novel or
highly differentiated in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company&#146;s mission is to bring transformational medicines to patients through innovation. <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
innovative pipeline of more than 10 clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage drug candidates is driven by the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-PoC</FONT></FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(Proof-of-Concept)</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Fast-to-Market</FONT></FONT> development strategies through internal R&amp;D and
global partnerships. The Company is on track to become a fully integrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> global biopharmaceutical company with cutting-edge discovery platforms, proven
preclinical and clinical development expertise, and world-class GMP manufacturing capabilities. <FONT STYLE="white-space:nowrap">I-Mab</FONT> has offices in Beijing, Shanghai, Hong Kong and Maryland, United States. For more information, please visit
<FONT STYLE="white-space:nowrap">http://ir.i-mabbiopharma.com</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities
laws, including statements regarding data from the eftansomatropin (TJ101) Phase III trial of pediatric growth hormone deficiency, the potential implications of clinical data for patients, and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT>
advancement of, and anticipated clinical development, regulatory milestones and commercialization of eftansomatropin (TJ101). Actual results may differ materially from those indicated in the forward-looking statements as a result of various
important factors, including but not limited to <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further
development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> drug candidates;
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to achieve commercial success for its drug candidates, if approved; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain and maintain protection of intellectual property
for its technology and drugs; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> reliance on third parties to conduct drug development, manufacturing and other services; <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> limited operating
history and <FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s clinical development, commercial and other operations, as well as those risks more fully discussed in the &#147;Risk Factors&#148; section in <FONT
STYLE="white-space:nowrap">I-Mab&#146;s</FONT> most recent annual report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in
<FONT STYLE="white-space:nowrap">I-Mab&#146;s</FONT> subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to <FONT STYLE="white-space:nowrap">I-Mab,</FONT>
and <FONT STYLE="white-space:nowrap">I-Mab</FONT> undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please contact: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">I-Mab</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jielun
Zhu, CFO </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> <FONT STYLE="white-space:nowrap">jielun.zhu@i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6057 8000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gigi Feng, Vice President and
Global Head of Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: <FONT STYLE="white-space:nowrap">gigi.feng@i-mabbiopharma.com</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6057 8000 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Inquiries: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Burns McClellan, Inc. (Americas and Europe) </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Steve Klass
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> sklass@burnsmc.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +1 212 213 0006 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Piacente Group, Inc. (Asia)
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emilie Wu </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> emilie@thepiacentegroup.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office line: +86 21 6039 8363 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g91622g0804183017047.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g91622g0804183017047.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& ,(# 2(  A$! Q$!_\0
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MJ!5NBBO-C",%:*L>N%%%%4 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
